YESWEHACK/ATG
1.12.2021 10:02:10 CET | Business Wire | Press release
YesWeHack , Europe’s leading bug bounty platform has partnered with Sweden headquartered ATG , to identify potential vulnerabilities on its exposed assets. ATG provides quality excitement and entertainment through horse betting, sports betting and casino games for approximately 1.4 million customers.
ATG is constantly evolving to meet new technology demands, increased data access, faster connections, and new digital channels. It is at the forefront of using digital technology to offer content-rich, personalised, and constantly available entertainment while meeting stricter regulation, digitalisation, and higher customer demands.
Like other industries that retain extensive customer data, the sports betting and gambling industry is particularly vulnerable to cyber threats. In addition to the games themselves, ATG maintains databases that contain a wealth of private and financial information. It has payment systems and apps that hackers can target. Meanwhile, one of the most significant challenges in the sports betting industry is match-fixing, which is unlawful manipulation of the sports results.
ATG strongly emphasises guarding against cybersecurity threats, especially as mobile and online transactions become the norm. It continuously reviews its offering, having frequently conducted penetration testing in the past. It is now planning to level up its security posture, and the bug bounty program with YesWeHack will play a crucial role in securing its platforms, thus reinforcing the trust of its partners and customers towards the ATG brand.
YesWeHack bug bounty programs offer a modern solution since testing is not limited to a small set of testers. Crowdsourced security will help ATG access a diverse range of security researchers, also called hunters, with unique specialisation and in-depth knowledge of the industry. ATG has started with a private bug bounty program where YesWeHack invited selected researchers to confirm the high level of security of ATG’s platform. This will soon be followed by a public bug bounty program where the platforms will be scrutinised by the entire YesWeHack community, representing more than 30,000 global cybersecurity researchers.
“ATG aims to combine our tradition and values with modern technology to improve and develop the gaming experience constantly,” said Erik Täfvander, Head of Cyber Security at ATG. “Our experience with YesWeHack has been stellar right from the beginning, and we hope to address every conceivable vulnerability on our platform that needs to be taken care of before it is exposed,” he added.
“ATG has a strong focus to create a positive gaming experience and wants to serve as an example for the betting industry,” said Guillaume Vassault-Houlière, CEO and Co-Founder of YesWeHack. “Adopting game-changing technologies such as bug bounty clearly shows that they are ahead of the competition and racing to win the hearts of their customers,” he added.
ATG will share their experience and best tips on how to get the most out of the ethical hackers community in a Webinar on December 7th. For more information: Blog post and Registration
ABOUT YESWEHACK
Founded in 2015, YesWeHack is the #1 European Bug Bounty & VDP Platform. YesWeHack offers companies an innovative approach to cybersecurity with Bug Bounty (pay-per-vulnerability discovered), connecting more than 30,000 cybersecurity experts (ethical hackers) across 170 countries with organizations to secure their exposed scopes and reporting vulnerabilities in their websites, mobile apps, infrastructure and connected devices. YesWeHack runs private and public programs for hundreds of organizations worldwide in compliance with the strictest European regulations.
In addition to the Bug Bounty platform, YesWeHack also offers: a creation and management solution for Vulnerability Disclosure Policy (VDP), a learning platform for ethical hackers called Dojo and a training platform for educational institutions, YesWeHackEDU. For more information: www.yeswehack.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211201005074/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 16:44:00 CET | Press release
One SKU. Every market. Connectivity decided at the end of production. Live at electronica 2026. Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the pr
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom